Insights

At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...

At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.

Inhye Ahn, MD, shares insight into the real-world practice impact of the FDA approval of non-covalent Bruton tyrosine kinase inhibitor pirtobrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have...

Inhye Ahn, MD, discusses next steps for investigating applications of pirtobrutinib in the current treatment paradigm for patients with chronic lymphocytic leukemia.

Tycel Phillips, MD, reviews the latest updates and developments in both the frontline and relapsed/refractory treatment landscape for patients with mantle cell lymphoma.

At the 2024 Great Debates & Updates meeting, Tycel Phillips, MD, participated in a debate about the role of non-chemotherapy regimens for the treatment of patients with newly diagnosed mantle cell lymphoma.

Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.

At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...

Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.

John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.